Zolazepam hydrochloride
CAS: 33754-49-3
Ref. 3D-FZ61533
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar | ||
50mg | A consultar |
Información del producto
- 4-(2-fluorophenyl)-1,3,8-trimethyl-6,8-dihydropyrazolo[3,4-e][1,4]diazepin-7(1H)-one hydrochloride (1:1)
- 4-(o-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1H)-one monohydrochloride
- Ci 716
- Pyrazolo(3,4-e)(1,4)diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, monohydrochloride
- Pyrazolo[3,4-e][1,4]diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, hydrochloride (1:1)
- Telazol
- Unii-45Sj093Q1N
- Zolazepam HCl
- Zolazepam hydrochloride [USAN]
- 4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1H)-one monohydrochloride
- Ver más sinónimos
Zolazepam is a benzodiazepine that has antinociceptive properties and is used as an anesthetic. The effective dose of zolazepam in humans is 5-10 mg intravenously, with a maximum dose of 25 mg. Zolazepam has been found to have no effect on systolic blood pressure or heart rate, but does cause significant reduction in terminal half-life. Zolazepam's antinociceptive effects are mediated through the inhibition of calcium ion channels, which results in decreased neuronal activity in the spinal cord and brainstem. Zolazepam causes sedation and immobilization by suppressing the function of neurons that control skeletal muscles.
Zolazepam also has been shown to inhibit osteoclast formation, which may be beneficial for patients with metabolic bone diseases such as Paget's disease or osteoporosis.
Propiedades químicas
Consulta técnica sobre: 3D-FZ61533 Zolazepam hydrochloride
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.